Scientists have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, a frequently incurable form of cancer. New research findings suggest that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor that targets the SRC gene to efficiently trigger cell death in AML cells.
New combination treatment strategy dramatically increases cell death in leukemia
